Denali Therapeutics UBS Global Biopharma Conference 2026
Review the key takeaways and the transcript of this earnings call.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
All right. Well, thank you so much for joining us on our next session. I'm Michael Yee, Global Head of Biotech Research here at UBS. Very excited to have members of the team from Denali Therapeutics up here with us. Ryan Watts, Chief Executive Officer, Katie Peng, Chief Commercial Officer. We get to talk about commercial sales, revenues, raising guidance recently. Alex Schuth, Chief Financial and Operating Officer. Great to see you guys.
Great to be here. Thanks, Mike.
Great to be here. Yeah.
Look, 2026 has been a transformative year for Denali. You got your first approval, been launching your product and raising guidance, as I said. Obviously, so much pipeline here. I told my colleagues we don't have time to go through all six of these programs, so we'll try to keep it focused. I think obviously most important, it's critical to talk about the approval and the successful launch of AVLAYAH, if I got that right.
That's perfect. Perfect, AVLAYAH. I would love to talk about that.
Ryan, why don't you take a chance to tell us about how the progress of that launch is going? Maybe Katie could talk a little bit about how that's going as well, because you raised guidance. As I was commenting with Alex, all this has happened, but then the stock goes up and it comes back down, so we're a little bit puzzled by that. Maybe you could have the opportunity to tell investors about how the launch is going.
Yeah, absolutely. Great to be here, Mike. Thanks for the invitation. Love being here in London. Just a quick introduction, I will hand it to Katie on the launch. As you pointed out, a transformative year, probably the simplest way to describe Denali now is that we have a product in AVLAYAH that validates our platform, the TransportVehicle platform, which then enables our pipeline.
Yep. I think my sense is, first of all, from a company perspective, it's been an extraordinary year.
It's really exciting to launch a product, especially many of the scientists who invented the TransportVehicle, who have been involved in its development, and now ultimately in this launch, have been with us now for the 11 years of our existence. What we're seeing is this incredible experience in the patient community. I think that's most exciting, to see the impact that AVLAYAH is having. In addition to that, now knowing that we can take our platform and apply it to other products. I think the question is, how big can Hunter be? How big can Hunter and Sanfilippo together be?
This platform is not just about treating enzyme replacement therapies or replacing enzyme replacement therapies with molecules that can cross the blood-brain barrier or improve delivery to brain or muscle, but it's also about using this technology in Alzheimer's disease.
We'll get to those, because those are multi-multi-billion.
Exactly. More and more data is coming out proving it works.
In terms of the launch, I'm going to hand it to Katie to give us an update.
Great. I mean, specifically on the launch, we're super pleased with the trajectory. We reported close to $18 million last quarter, which was significantly higher than our $10 million-$12 million in guidance. Largely, that is driven by the acceleration of payer access. We were able to unlock commercial and Medicaid payment very quickly. In addition, we had a great bolus of our EAP patients, our clinical trial patients, come onto treatment in Q3, which was much sooner than we expected. Those patients were all at the highest dose. In addition, we've heard tremendous feedback from physicians and especially from the families on how well the patients are doing on AVLAYAH. We also discussed bringing in the S-shaped curve.
We talked about rare disease launches having this S-shaped curve, but that we are bringing that inflection in sooner because of the momentum we're seeing behind the launch. We said, between Q2 and Q3, that's probably not the run rate you would expect to see, but we expect strong growth, especially between 2026 and 2027. That inflection is coming, and we're building on a very strong patient base. Generally, in rare disease, persistence is high, so we expect really good, strong growth.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.
View the full transcript with ProCall participants
3 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
